ProfileGDS5678 / 1449741_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 68% 68% 67% 68% 72% 73% 69% 68% 69% 69% 68% 72% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4356171
GSM967853U87-EV human glioblastoma xenograft - Control 24.1691168
GSM967854U87-EV human glioblastoma xenograft - Control 34.2033368
GSM967855U87-EV human glioblastoma xenograft - Control 44.1396167
GSM967856U87-EV human glioblastoma xenograft - Control 54.1523868
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5323472
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6585773
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.294569
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1849268
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2530469
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2470569
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1789468
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5884372
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.261669